These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28953788)

  • 21. Pathophysiology of schizophrenia and the role of newer antipsychotics.
    Risch SC
    Pharmacotherapy; 1996; 16(1 Pt 2):11-4. PubMed ID: 8778681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.
    Dold M; Samara MT; Li C; Tardy M; Leucht S
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD009831. PubMed ID: 25592299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders.
    Wierońska JM; Pilc A
    Pharmacol Ther; 2019 Jan; 193():75-82. PubMed ID: 30149102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis.
    Squires RF; Saederup E
    Neurochem Res; 1991 Oct; 16(10):1099-111. PubMed ID: 1686635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
    Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
    JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.
    Bonoldi I; Howes OD
    CNS Drugs; 2014 Jul; 28(7):649-63. PubMed ID: 24919790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benzodiazepines in the treatment of schizophrenia: an updated survey.
    Lingjaerde O
    Acta Psychiatr Scand; 1991 Nov; 84(5):453-9. PubMed ID: 1685616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
    Carpiniello B; Mellino G; Pintore S; Puddu L; Pinna F
    Clin Ter; 2011; 162(4):331-41. PubMed ID: 21912821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review.
    Sim F; Sweetman I; Kapur S; Patel MX
    J Psychopharmacol; 2015 Feb; 29(2):212-23. PubMed ID: 25049261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.
    Iyo M; Tadokoro S; Kanahara N; Hashimoto T; Niitsu T; Watanabe H; Hashimoto K
    J Clin Psychopharmacol; 2013 Jun; 33(3):398-404. PubMed ID: 23609386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A biochemical theory of schizophrenia].
    Kornhuber HH; Kornhuber J; Kim JS; Kornhuber ME
    Nervenarzt; 1984 Nov; 55(11):602-6. PubMed ID: 6151120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study.
    Molina JD; Lerma-Carrillo I; Leonor M; Pascual F; Blasco-Fontecilla H; González-Parra S; López-Muñoz F; Alamo C
    Clin Neuropharmacol; 2009; 32(1):10-5. PubMed ID: 18978498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sedation in acute and chronic agitation.
    Levy RH
    Pharmacotherapy; 1996; 16(6 Pt 2):152S-159S; discussion 166S-168S. PubMed ID: 8947999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
    Patil ST; Zhang L; Martenyi F; Lowe SL; Jackson KA; Andreev BV; Avedisova AS; Bardenstein LM; Gurovich IY; Morozova MA; Mosolov SN; Neznanov NG; Reznik AM; Smulevich AB; Tochilov VA; Johnson BG; Monn JA; Schoepp DD
    Nat Med; 2007 Sep; 13(9):1102-7. PubMed ID: 17767166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia.
    Wolkowitz OM; Turetsky N; Reus VI; Hargreaves WA
    Psychopharmacol Bull; 1992; 28(3):291-5. PubMed ID: 1362277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.
    Sonnenschein SF; Grace A
    Expert Opin Ther Targets; 2021 Jan; 25(1):15-26. PubMed ID: 33170748
    [No Abstract]   [Full Text] [Related]  

  • 38. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sleep disturbances in patients with schizophrenia : impact and effect of antipsychotics.
    Cohrs S
    CNS Drugs; 2008; 22(11):939-62. PubMed ID: 18840034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synaptically released glutamate reduces gamma-aminobutyric acid (GABA)ergic inhibition in the hippocampus via kainate receptors.
    Min MY; Melyan Z; Kullmann DM
    Proc Natl Acad Sci U S A; 1999 Aug; 96(17):9932-7. PubMed ID: 10449797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.